Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analgesic Comparative Trials Urged; Placebo Still Standard for Approval

Executive Summary

FDA should encourage sponsors to conduct comparisons between standard analgesic therapies and newer agents, Arthritis Committee guest Mitchell Max, MD, National Institutes of Health, suggested

You may also be interested in...



Chronic Pain Standard Proposed By FDA Too Strict, Four Trials OK, Cmte Says

Global chronic pain can be an appropriate Rx analgesic indication, but the revised clinical trial requirements under consideration by FDA may be too stringent, Arthritis Advisory Committee members said

Analgesic Acute Pain Trials Should Assess Long-Term, Multi-Dose Safety

Analgesic acute pain trails should assess long-term safety and multiple doses, members of FDA's Arthritis Advisory Committee suggested July 30

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

PS040286

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel